Concerning other investigational therapies that act at the alarmin level, ipetekimab is a monoclonal antibody directed at the alarmin IL-33 that is being investigated in type 2 inflammatory diseases, including moderate-to-severe asthma. This evidence concerns the gene IL33 and asthma.